Global Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)-Forecast to 2035

Human Vaccines Market Overview

As per MRFR analysis, the Human Vaccines Market Size was estimated at 48.22 (USD Billion) in 2024.The Human Vaccines Market Industry is expected to grow from 50.22(USD Billion) in 2025 to 78.5 (USD Billion) by 2035. The Human Vaccines Market CAGR (growth rate) is expected to be around 4.14% during the forecast period (2025-2035).

Key Human Vaccines Market Trends Highlighted

The Global Human Vaccines Market is witnessing significant trends driven by various market factors. A key market driver is the increasing prevalence of infectious diseases and the need for preventative healthcare measures. With growing awareness of vaccination benefits, governments and healthcare organizations are investing in vaccination programs to prevent outbreaks and enhance public health. 

This heightened focus on preventive healthcare is leading nations to support initiatives aimed at increasing vaccination coverage and developing innovative vaccines. Opportunities to be explored in this market include advancements in vaccine technology, such as mRNA technology and personalized vaccines.

As researchers continue to innovate, there is potential for the introduction of new and effective vaccine formulations that cater to specific populations and evolving pathogens. Furthermore, as global travel increases and disease patterns change, there is an increasing demand for vaccines that address emerging infectious diseases, presenting a chance for companies to develop specialized products. 

In recent times, trends show a significant increase in public-private partnerships to facilitate vaccine research and distribution, as seen during the COVID-19 pandemic. This collaboration has not only expedited vaccine development timelines but has also highlighted the importance of global cooperation in addressing health crises.

Furthermore, the push towards universal vaccination programs to ensure equitable access across diverse populations has gained momentum, reflecting a commitment to global health security. Overall, these trends underscore a dynamic environment where innovation, collaboration, and public health priorities shape the future of the Global Human Vaccines Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Human Vaccines Market Drivers

Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases globally acts as a significant driver for the Global Human Vaccines Market Industry. Recent data from the World Health Organization indicates that infectious diseases such as influenza, hepatitis, and measles have been reported to increase annually, with measles cases alone rising by 558 percent globally between 2017 and 2019. This alarming trend underscores the urgent need for effective vaccination programs to combat these diseases.

Organizations such as the Global Vaccine Alliance and the Center for Disease Control and Prevention are crucial in promoting vaccine advocacy and supporting vaccination efforts worldwide. As governments increasingly prioritize public health initiatives related to vaccination, the market for human vaccines is projected to grow substantially, driven by a shared commitment to control infectious diseases across regions.

Growing Investment in Research and Development

There has been substantial growth in the investment in Research and Development (R) in the Global Human Vaccines Market Industry. It is reported that global funding for vaccine R has increased by approximately 25 percent over the past five years, encouraged by public health organizations such as the Coalition for Epidemic Preparedness Innovations. R advancements lead to the development of new and more effective vaccines, addressing a wider range of diseases thereby increasing the market size.

Furthermore, government initiatives worldwide, such as research grants and funding opportunities, further bolster the potential for innovative vaccine solutions, enhancing the competitive landscape of the industry and paving the way for new entrants.

Growing Public Awareness Immunization

Public awareness and education regarding the importance of vaccination are critical market drivers in the Global Human Vaccines Market Industry. Campaigns led by organizations such as UNICEF and the World Health Organization have successfully increased global vaccination rates. For instance, immunization coverage for vaccines like the DTP (Diphtheria, Tetanus, and Pertussis) vaccine has risen to over 85 percent globally, as reported in recent UNICEF statistics.

As individuals become more informed about the benefits of immunization, this awareness translates into higher demand for vaccines, driving market growth. Consequently, governments and organizations focusing on public outreach and education in the realm of vaccination will play a pivotal role in shaping future market trends.

Human Vaccines Market Segment Insights

Human Vaccines Market Vaccine Type Insights

The Global Human Vaccines Market is poised for considerable growth, with a notable focus on the Vaccine Type segment, which includes various classifications like Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines. The overall market is expected to witness a substantial rise, with projections indicating a value of 50.22 USD Billion in 2024 and reaching 78.5 USD Billion by 2035. Within this landscape, the Inactivated segment holds the majority, valued at 15.0 USD Billion in 2024 and projected to grow to 23.0 USD Billion by 2035.

This segment is vital due to its effectiveness in immunizing against a range of diseases without causing the infection itself, making it a safe choice for broad population use. Following closely is the Live Attenuated segment, expected to be valued at 10.0 USD Billion in 2024 and rise to 15.5 USD Billion by 2035. Live Attenuated vaccines are significant as they offer robust immunity and often require fewer doses, thereby ensuring better compliance among different demographics. 

The Subunit vaccines are valued at 8.0 USD Billion in 2024, increasing to 12.0 USD Billion by 2035, which makes them critical due to their ability to use only specific parts of the virus or bacteria, reducing side effects while maintaining efficacy.

The Recombinant segment is anticipated to reach 11.0 USD Billion in 2024 and ascend to 17.0 USD Billion by 2035, and its importance lies in creating highly specific proteins that elicit a strong immune response, making them a popular choice in the vaccine landscape. Lastly, the Toxoid vaccines, valued at 6.22 USD Billion in 2024 and expected to mature into an 11.0 USD Billion market by 2035, emphasize their crucial role in neutralizing toxins produced by pathogens, thus preventing the diseases they cause. 

The Global Human Vaccines Market is characterized by continuous innovations in vaccine technology and an increasing focus on preventive healthcare, driving the imperative for effective vaccines across the globe.Each Vaccine Type carries its significance, displaying critical attributes that cater to specific public health needs, thereby making the Global Human Vaccines Market a dynamic and vital sector for global health advancements.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Human Vaccines Market Application Insights

This segment encompasses critical applications including Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Influenza Vaccines. Preventive Vaccines are crucial in preventing infectious diseases, thus significantly impacting global health outcomes. Furthermore, Therapeutic Vaccines are gaining traction in treating chronic diseases and cancers, leading to innovations in Research and Development.

Travel Vaccines cater to health-conscious travelers, promoting safety and disease prevention across borders, while Influenza Vaccines remain essential given the seasonal outbreaks, ensuring community health is prioritized. With such diverse applications, the Global Human Vaccines Market revenue is set to expand, backed by rising public health initiatives and awareness around vaccine benefits, despite challenges such as logistics and public skepticism. Understanding this landscape through Global Human Vaccines Market segmentation is vital for stakeholders to harness opportunities and enhance vaccine accessibility.

Human Vaccines Market Administration Route Insights

The Administration Route plays a crucial role in this market, as it encompasses various methods used to deliver vaccines effectively. This segmentation includes routes such as Intramuscular, Subcutaneous, Oral, and Intradermal administration, each of which presents unique advantages. Intramuscular administration is particularly notable for its rapid immune response, making it a preferred choice for many vaccines, including those targeting diseases like influenza and COVID-19

.Subcutaneous routes are gaining traction due to their ease of administration, especially for patients who require self-administration. Oral vaccination presents an innovative approach that can improve accessibility and adherence, while Intradermal administration is being explored for its potential to reduce vaccine dosages and improve immunogenicity. As the Global Human Vaccines Market data shows, the increasing focus on vaccination programs worldwide, along with advances in vaccine delivery technologies, is a driving force behind the growth and significance of these administration routes.

The ongoing challenges of vaccine hesitancy and logistical issues create pathways for innovative solutions in this sector. The Global Human Vaccines Market statistics suggest that the various administration methods are integral to achieving widespread vaccine coverage and combating infectious diseases on a global scale.

Human Vaccines Market Target Diseases Insights

The landscape is primarily shaped by various diseases, including Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. Infectious Disease vaccines remain crucial due to their role in preventing outbreaks and protecting public health, while Oncological Diseases vaccines are gaining importance in cancer prevention and treatment, reflecting advancements in Research and Development.

Autoimmune Diseases, often complex and diverse, present significant challenges for vaccine development yet represent a growing area of interest for addressing chronic health issues. The increasing prevalence of these diseases, coupled with technological advancements and a growing understanding of the immune system, contributes to the market growth. With a compound annual growth rate of 4.14 expected for the period from 2025 to 2035, the sector is well-positioned to adapt to emerging health challenges while continuously making strides in vaccine effectiveness and safety.

The Global Human Vaccines Market statistics indicate a trend toward personalized and targeted therapies, emphasizing the importance of addressing diverse health needs on a global scale.

Human Vaccines Market Regional Insights

The Global Human Vaccines Market is characterized by diverse regional dynamics shaping its growth trajectory. In 2024, North America leads with a valuation of 20.0 USD Billion, expected to grow to 32.0 USD Billion by 2035, reflecting significant investments in Research and Development and robust healthcare infrastructure. Europe follows with a market value of 12.5 USD Billion in 2024, projected to rise to 20.0 USD Billion, highlighting the region's focus on innovation and advanced immunization strategies. 

The Asia-Pacific (APAC) region is projected to reach 10.0 USD Billion in 2024, with growth anticipated to 15.0 USD Billion, driven by a rapidly expanding population and increasing healthcare accessibility.South America is valued at 4.0 USD Billion in 2024, growing to 6.0 USD Billion, showcasing improvements in vaccination coverage amidst economic advancements. The Middle East and Africa (MEA) hold a current market value of 3.72 USD Billion, progressing to 5.5 USD Billion, as investments in healthcare infrastructure rise, enhancing vaccine delivery systems. 

The dominance of North America, in particular, underscores the significant role of regulatory frameworks and funding in vaccine development, while the growth in APAC indicates a burgeoning demand for vaccines amid increasing healthcare expenditure.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Human Vaccines Market Key Players and Competitive Insights

The Global Human Vaccines Market is characterized by robust competition and constant innovation, driven by the critical importance of vaccines in preventing diseases and safeguarding public health. As the market expands, various pharmaceutical companies vie for leadership, investing heavily in research and development to create more effective vaccine solutions. 

Factors such as increasing prevalence of infectious diseases, emerging global health threats, and the rising demand for vaccines worldwide are shaping the competitive landscape. As a result, companies are not only focusing on advanced research but also forming strategic alliances and partnerships, which enhance their capabilities in delivering innovative vaccine options to meet global health needs.

Pfizer has established itself as a formidable player in the Global Human Vaccines Market, underpinned by its extensive portfolio and deep-rooted commitment to vaccine development. The company’s strengths lie in its advanced technological platforms and strong RD capabilities, which allow it to deliver a wide range of vaccines targeting various infectious diseases.

 Pfizer’s global presence is reinforced through its strategic partnerships, collaborations with healthcare organizations, and robust distribution networks, enabling it to reach diverse markets effectively. The company's significant investment in innovative vaccine research has resulted in breakthroughs that have addressed urgent global health concerns, further solidifying its position in the competitive landscape.

Merck and Co a significant footprint in the Global Human Vaccines Market, focusing on the development of innovative vaccines and therapeutic solutions for infectious diseases. Renowned for its key products, Merck offers vaccines that target diseases such as HPV, measles, and influenza. The company has been proactive in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate novel technologies and enhance its research capabilities. 

Merck’s strong emphasis on vaccine development is reflected in its commitment to global health initiatives aimed at increasing accessibility and expanding immunization programs. Its well-established reputation for high-quality products and strong pipeline of vaccine candidates positions Merck as a leader in the market committed to advancing public health through continuous innovation and responsive product offerings.

Key Companies in the Human Vaccines Market Include

• Pfizer


• Merck and Co


• AbbVie


• Roche


• Gilead Sciences


• Johnson and Johnson


• Bristol Myers Squibb


• Novartis


• Regeneron Pharmaceuticals


• Bayer


• Moderna


• AstraZeneca


• GlaxoSmithKline


• Sanofi

Human Vaccines Market Industry Developments

Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety.

Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally.

In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges.

Human Vaccines Market Segmentation Insights

Human Vaccines Market Vaccine Type Outlook

• Inactivated


• Live Attenuated


• Subunit


• Recombinant


• Toxoid

Human Vaccines Market Application Outlook

• Preventive Vaccines


• Therapeutic Vaccines


• Travel Vaccines


• Influenza Vaccines

Human Vaccines Market Administration Route Outlook

• Intramuscular


• Subcutaneous


• Oral


• Intradermal

Human Vaccines Market Target Diseases Outlook

• Infectious Diseases


• Oncological Diseases


• Autoimmune Diseases

Human Vaccines Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric	Details
Market Size 2024	48.22(USD Billion)
Market Size 2025	50.22(USD Billion)
Market Size 2035	78.5(USD Billion)
Compound Annual Growth Rate (CAGR)	4.14% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi
Segments Covered	Vaccine Type, Application, Administration Route, Target Diseases, Regional
Key Market Opportunities	Rising infectious disease outbreaks, Increasing vaccination awareness, Expansion of vaccine pipelines, Growth in healthcare funding, Advancements in vaccine technology
Key Market Dynamics	Increasing vaccine demand, Technological advancements, Government support and funding, Global health initiatives, Rising infectious diseases.
Countries Covered	North America, Europe, APAC, South America, MEA